Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nymox Pharm Corp (NYMX)

Nymox Pharm Corp (NYMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,691
  • Shares Outstanding, K 82,381
  • Annual Sales, $ 10 K
  • Annual Income, $ -11,740 K
  • 60-Month Beta 1.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NYMX with:

Options Overview

Details
  • Implied Volatility 146.59%
  • Historical Volatility 68.55%
  • IV Percentile 39%
  • IV Rank 15.31%
  • IV High 862.66% on 09/15/20
  • IV Low 17.16% on 11/10/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 66
  • Volume Avg (30-Day) 93
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 4,640
  • Open Int (30-Day) 4,447

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2515 +27.05%
on 07/27/21
1.6300 -2.45%
on 08/02/21
+0.0200 (+1.27%)
since 07/02/21
3-Month
1.2515 +27.05%
on 07/27/21
2.0973 -24.19%
on 06/07/21
-0.4000 (-20.10%)
since 04/30/21
52-Week
1.2515 +27.05%
on 07/27/21
3.5000 -54.57%
on 02/16/21
-1.6300 (-50.62%)
since 07/31/20

Most Recent Stories

More News
Nymox Announces Date for Fexapotide Filing

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the "Company") is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or...

NYMX : 1.5900 (+2.58%)
Nymox Announces $8,000,000 Private Placement

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the "Company") today announced it has entered into a definitive agreement with institutional investors in a private placement of 3,669,724 shares of common...

NYMX : 1.5900 (+2.58%)
Nymox Provides New Update on Regulatory Activities

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide the latest update on the Company's regulatory filing preparation activities. The Company expects to file for approval for its first...

NYMX : 1.5900 (+2.58%)
Nymox Provides Update on Regulatory Filing Activities

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment...

NYMX : 1.5900 (+2.58%)
Nymox: 3Q Earnings Snapshot

NASSAU, Bahamas (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Friday reported a loss of $4.2 million in its third quarter.

NYMX : 1.5900 (+2.58%)
Nymox: 2Q Earnings Snapshot

NASSAU, Bahamas (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Monday reported a loss of $2.9 million in its second quarter.

NYMX : 1.5900 (+2.58%)
Nymox Announces $9 Million Registered Direct Offering

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock...

NYMX : 1.5900 (+2.58%)
Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of...

NYMX : 1.5900 (+2.58%)
Nymox: 1Q Earnings Snapshot

ST. LAURENT, Quebec (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Thursday reported a loss of $2.6 million in its first quarter.

NYMX : 1.5900 (+2.58%)
Nymox Announces Important New Patent Developments

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international patents concerning the Company's prostate enlargement and prostate cancer...

NYMX : 1.5900 (+2.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nymox Pharmaceutical Corporation is engaged in the research and development of drugs and diagnostic products. The company offers products such as AlzheimAlert, NicAlert and TobacAlert tests. It markets its products primarily in the United States, Canada, and Europe. Nymox Pharmaceutical Corporation is...

See More

Key Turning Points

3rd Resistance Point 1.6967
2nd Resistance Point 1.6633
1st Resistance Point 1.6267
Last Price 1.5900
1st Support Level 1.5567
2nd Support Level 1.5233
3rd Support Level 1.4867

See More

52-Week High 3.5000
Fibonacci 61.8% 2.6411
Fibonacci 50% 2.3758
Fibonacci 38.2% 2.1104
Last Price 1.5900
52-Week Low 1.2515

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar